Clincosm LogoSign in Get a demo

RACR2: Registry for Asthma Characterization and Recruitment 2

Sponsor
National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Overall Status
Completed
CT.gov ID
NCT02513264
Collaborator
Inner-City Asthma Consortium (Other)
1,384
Enrollment
10
Locations
59
Duration (Months)
138.4
Patients Per Site
2.3
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

There is a need for people to take part in research studies to learn more about diseases and how to treat them. The Registry for Asthma Characterization and Recruitment 2 (RACR2) will create a database of participants with asthma and nasal allergies, or risk factors for these conditions, who are potentially eligible for future Inner City Asthma Consortium (ICAC) trials. The registry database will include assessments of various asthma and allergy characteristics to achieve a more efficient, selective recruitment of these participants for other protocols.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The overall goal of the Registry for Asthma Characterization and Recruitment 2 (RACR2) is to create a database of participants who are potentially eligible for future Inner City Asthma Consortium (ICAC) clinical research studies. The registry will provide an avenue to assess various asthma and allergy characteristics, which will result in more efficient recruitment for current and future ICAC protocols.

    Potential participants will be recruited via telephone or in person. Those deemed potentially eligible for a current protocol or protocol in development may be invited to the clinic for further data collection and assessments. This registry allows flexibility in selecting the eligibility criteria and data collection to match planned or upcoming ICAC protocols. At each stage of data collection, participants may be discontinued, put on hold, or invited to participate in further screening activities, depending on the likelihood that they will qualify for a future protocol. Participants may opt to withdraw their information or discontinue from the registry at any time, in person, by telephone, or in writing.

    Study Design

    Study Type:
    Observational [Patient Registry]
    Actual Enrollment :
    1384 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Registry for Asthma Characterization and Recruitment 2 (ICAC-25)
    Study Start Date :
    Apr 14, 2015
    Actual Primary Completion Date :
    Mar 13, 2020
    Actual Study Completion Date :
    Mar 13, 2020

    Outcome Measures

    Primary Outcome Measures

    1. Number of participants with asthma and allergy characteristics [Year 7]

      Characteristics of the participants enrolled in the registry will be assessed on a periodic basis (descriptive summary of diagnosis and parameters associated with the former).

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    1 Year to 55 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    Eligibility criteria vary depending on recruitment needs for future ICAC protocols. Participants with asthma and participants without asthma, atopy, and rhinitis may be recruited at the same time or different times, depending on recruitment needs.

    Certain characteristics or groups of characteristics within each criterion may be selected for periods of time across clinical sites or at each individually participating clinical site. For example, over a 6-month period, the Consortium could decide to recruit children aged 6 through 12 years with diagnosed asthma who have asthma symptoms, have a history of an asthma exacerbation, and reside in prespecified census tracts within the metropolitan statistical area. During selective recruitment periods, individuals who meet broader criteria may or may not be enrolled at the discretion of the Consortium.

    1. All participants must resides within the metropolitan statistical area that includes the clinical site.

    2. Participants with asthma are defined by having evidence of asthma. Evidence of asthma is defined by meeting at least one of the following criteria:

    • Clinician-diagnosed asthma

    • Asthma symptoms, history of an asthma exacerbation, or current use of asthma medication(s)

    • Recurrent wheezing

    • Wheezing apart from a cold

    At times of selective recruitment, participants with asthma may be required to meet more selective criteria above and may be required to meet one or more of the criteria in risk factors for asthma. Evidence of risk factors for asthma is defined by meeting at least one of the following criteria:

    • Parental history of asthma

    • Eczema or atopic dermatitis

    • Reported allergies to pets, food, indoor allergens, or outdoor allergens

    • Allergic sensitization by results of allergy skin testing or results of serum immunoglobulin E (IgE) testing

    • Rhinitis

    1. Participants without asthma, atopy, and rhinitis must meet all of the following:

    • Negative history of an asthma diagnosis by a clinician

    • Negative history of a diagnosis of atopic dermatitis or eczema by a clinician

    • Negative history of a rhinitis diagnosis by a clinician

    • A forced expiratory volume at 1 second (FEV1) >= 5% predicted

    • Negative prick skin-tests to any of a panel of indoor and outdoor allergens

    • No current asthma as determined by the appropriate case report form

    • No current chronic rhinitis/sinusitis as determined by the appropriate case report form

    Exclusion Criteria:
    An individual who meets any of the following criteria will be excluded from enrollment:

    1. Has any of the following chronic medical conditions: cardiac condition requiring daily medication, seizure disorder requiring daily medication, obvious severe mental retardation that prevents the participant from answering questions or following instructions, cystic fibrosis, immune deficiency, type 1 diabetes, allergic bronchopulmonary aspergillosis, or any other chronic medical condition at the discretion of the registry clinician

    2. Does not primarily speak English (or Spanish at clinical sites with Spanish-speaking staff)

    3. Has a primary caretaker who does not speak English (or Spanish at clinical sites with Spanish-speaking staff; not applicable if participant is able to provide consent)

    4. Is a foster child (not applicable if participant is able to provide consent)

    5. Is unwilling to sign the written informed consent form if of age, or parent/legal guardian is unwilling to sign the written informed consent if participant is not of age

    6. Is unwilling to sign the assent form, if age appropriate

    Participants who are pregnant will not be excluded or discontinued from RACR2 but will not undergo any procedures that are prohibited during pregnancy.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Children's Hospital Colorado Aurora Colorado United States 80045
    2 Children's National Medical Center Washington District of Columbia United States 20010
    3 Ann and Robert Lurie Children's Hospital of Chicago Chicago Illinois United States 60611
    4 Johns Hopkins University Baltimore Maryland United States 21205
    5 Boston Medical Center Boston Massachusetts United States 02118
    6 Henry Ford Health System Detroit Michigan United States 48202
    7 St. Louis Children's Hospital Saint Louis Missouri United States 63110
    8 Columbia University Medical Center New York New York United States 10032
    9 Cincinnati Children's Hospital Cincinnati Ohio United States 452229
    10 University of Texas Southwestern Medical School Dallas Texas United States 75390

    Sponsors and Collaborators

    • National Institute of Allergy and Infectious Diseases (NIAID)
    • Inner-City Asthma Consortium

    Investigators

    • Principal Investigator: Jacqueline Pongracic, M.D., Ann & Robert H Lurie Children's Hospital of Chicago
    • Principal Investigator: Edward M. Zoratti, M.D., Henry Ford Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    National Institute of Allergy and Infectious Diseases (NIAID)
    ClinicalTrials.gov Identifier:
    NCT02513264
    Other Study ID Numbers:
    • DAIT ICAC-25
    First Posted:
    Jul 31, 2015
    Last Update Posted:
    Jan 25, 2021
    Last Verified:
    Jan 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID)
    Registry
    Asthma
    Inner City Asthma Consortium (ICAC) study eligibility
    Additional relevant MeSH terms:
    Asthma

    Study Results

    No Results Posted as of Jan 25, 2021